- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
2024’s Biggest AI Stories
Artificial Intelligence took the industry by storm this year, but how is actually being implemented?
Stock.adobe.com
Huestis discusses the ways that quantum simulation and quantum systems can be used in areas such as drug discovery and the creation and protection of intellectual property in the life sciences industry.
How AI is Changing the Drug Development Journey
While no company has yet achieved the full promise of AI to radically accelerate time to market, meaningful strides are being made across the drug discovery funnel.
As AI continues to dominate the news, maximizing its potential is on every C-suite leader’s mind. Successful AI adoption, specifically in HCP marketing, will require a thoughtful, customer-centric approach to avoid aggravating the promotional fatigue and dissatisfaction fostered by drugmakers' dash toward digital1 since COVID-19. This article provides an overview of some key areas for AI integration that can help improve the HCP customer experience today and tomorrow.
The Impact of Technology on Commercialization: Q&A with Claus Zieler
The Astellas chief commercial officer discusses the impact that the increase in global and local connectivity has had on commercialization, among other trends.
Adoption Lag in AI: Q&A with Scott Snyder
EVERSANA’s chief digital officer discusses the current relationship between pharma and AI.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
